It is suggested that hepcidin downregulates ferroportin expression and dominantly controls the iron export activity of ferroportin in patients with cancer, Alzheimer’s disease, and anemia of chronic inflammation [28,29,30]. This evidence concerns the gene HAMP and anemia.